Covance Expands Global Biologics Capabilities
Covance announced it is expanding its large molecule bioanalytical space
Covance announced it is expanding its large molecule bioanalytical space co-located with Covance’s central laboratory facility in Indianapolis, IN to grow its global biologics capabilities. The expansion, which is planned to open during the second half of 2014, is doubling the company’s large molecule capacity. With this expansion, Covance expects to add 100 new positions over the next five years. This investment will enable Covance to further leverage its small and large molecule bioanalytical expertise while providing scientific, logistic, and regulatory synergies for clients.
Read the full release here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
